JP2009535295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535295A5 JP2009535295A5 JP2008558486A JP2008558486A JP2009535295A5 JP 2009535295 A5 JP2009535295 A5 JP 2009535295A5 JP 2008558486 A JP2008558486 A JP 2008558486A JP 2008558486 A JP2008558486 A JP 2008558486A JP 2009535295 A5 JP2009535295 A5 JP 2009535295A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- pharmaceutically acceptable
- formula
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- -1 cyano, carboxy Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CC(*1)C(C(*(CCN)C(OCOC(Cc(cc2)ccc2OC*=O)O)=O)=O)C(NC)=C1C(*(c(cc(cc1)C(*(C2CC2)=C)=O)c1N)=C)=*C=* Chemical compound CC(*1)C(C(*(CCN)C(OCOC(Cc(cc2)ccc2OC*=O)O)=O)=O)C(NC)=C1C(*(c(cc(cc1)C(*(C2CC2)=C)=O)c1N)=C)=*C=* 0.000 description 1
- RXOQFUPYDWQMGV-UHFFFAOYSA-N CCCN(C(c1c[nH]c(/C(/Nc2c(C)ccc(C(NCC)=O)c2)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCCN(C(c1c[nH]c(/C(/Nc2c(C)ccc(C(NCC)=O)c2)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O RXOQFUPYDWQMGV-UHFFFAOYSA-N 0.000 description 1
- RXOQFUPYDWQMGV-UHFFFAOYSA-O CCCN(C(c1c[nH]c(/C(/Nc2cc(C(NCC)=O)ccc2C)=N\C=[NH2+])c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCCN(C(c1c[nH]c(/C(/Nc2cc(C(NCC)=O)ccc2C)=N\C=[NH2+])c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O RXOQFUPYDWQMGV-UHFFFAOYSA-O 0.000 description 1
- FHAMLLHTTNYYGY-UHFFFAOYSA-N CCCN(C(c1c[nH]c(/C(/Nc2cc(C(Nc3n[o]cc3)=O)ccc2C)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCCN(C(c1c[nH]c(/C(/Nc2cc(C(Nc3n[o]cc3)=O)ccc2C)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O FHAMLLHTTNYYGY-UHFFFAOYSA-N 0.000 description 1
- ULWQQWNAKPDRHJ-UHFFFAOYSA-N CCCN(C(c1cc(Nc2ncn[n]3c2c(C)c(C(NCC)=O)c3)c(C)cc1)=O)C(OCOC(Cc(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCCN(C(c1cc(Nc2ncn[n]3c2c(C)c(C(NCC)=O)c3)c(C)cc1)=O)C(OCOC(Cc(cc1)ccc1OP(O)(O)=O)=O)=O ULWQQWNAKPDRHJ-UHFFFAOYSA-N 0.000 description 1
- XXUMYKVJUUHUEB-UHFFFAOYSA-O CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(C3CC3)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=[NH2+])c1)=O Chemical compound CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(C3CC3)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=[NH2+])c1)=O XXUMYKVJUUHUEB-UHFFFAOYSA-O 0.000 description 1
- QAZJMYXHPIIPGW-UHFFFAOYSA-N CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O Chemical compound CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O QAZJMYXHPIIPGW-UHFFFAOYSA-N 0.000 description 1
- SXOIAOFBNYMRBH-UHFFFAOYSA-N CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CCC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O Chemical compound CCCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CCC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O SXOIAOFBNYMRBH-UHFFFAOYSA-N 0.000 description 1
- BRFJNADDKDFONI-UHFFFAOYSA-N CCN(C(c1c[nH]c(/C(/Nc2c(C)ccc(C(Nc3n[o]cc3)=O)c2)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCN(C(c1c[nH]c(/C(/Nc2c(C)ccc(C(Nc3n[o]cc3)=O)c2)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O BRFJNADDKDFONI-UHFFFAOYSA-N 0.000 description 1
- AOPQZGIEIGZWOX-UHFFFAOYSA-N CCN(C(c1c[nH]c(/C(/Nc2cc(C(NC)=O)ccc2C)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O Chemical compound CCN(C(c1c[nH]c(/C(/Nc2cc(C(NC)=O)ccc2C)=N\C=N)c1C)=O)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O AOPQZGIEIGZWOX-UHFFFAOYSA-N 0.000 description 1
- PXFMLQXEEUWAMM-UHFFFAOYSA-N CCNC(c(c(C)c12)c[n]1ncnc2Nc1c(C)ccc(C(N(C2CC2)C(OCOC(Cc(cc2)ccc2OP(O)(O)=O)=O)=O)=O)c1)=O Chemical compound CCNC(c(c(C)c12)c[n]1ncnc2Nc1c(C)ccc(C(N(C2CC2)C(OCOC(Cc(cc2)ccc2OP(O)(O)=O)=O)=O)=O)c1)=O PXFMLQXEEUWAMM-UHFFFAOYSA-N 0.000 description 1
- SLMVYAGULWEEFL-KJFHWCLQSA-N CCNC(c1c[nH]c(/C(/N(C(OCOC(Cc(cc2)ccc2OC(O)O)=O)=O)c2c(C)ccc(C(NCC)=O)c2)=N\C=[N-])c1C)=O Chemical compound CCNC(c1c[nH]c(/C(/N(C(OCOC(Cc(cc2)ccc2OC(O)O)=O)=O)c2c(C)ccc(C(NCC)=O)c2)=N\C=[N-])c1C)=O SLMVYAGULWEEFL-KJFHWCLQSA-N 0.000 description 1
- DBFGWCDICZNDHB-UHFFFAOYSA-N CCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(C3CC3)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O Chemical compound CCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(C3CC3)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O DBFGWCDICZNDHB-UHFFFAOYSA-N 0.000 description 1
- YDIYJTCDPYEETR-UHFFFAOYSA-N CCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O Chemical compound CCNC(c1ccc(C)c(N/C(/c2c(C)c(C(N(CC)C(OCOC(c(cc3)ccc3OP(O)(O)=O)=O)=O)=O)c[nH]2)=N/C=N)c1)=O YDIYJTCDPYEETR-UHFFFAOYSA-N 0.000 description 1
- KZYFIDCFFKLEKC-USLOJTSYSA-N Cc1c(/C(/N(C(OCOC(Cc(cc2)ccc2OCC(O)=O)=O)=O)c2c(C)ccc(C(NC3CC3)=O)c2)=N\C=[N-])[nH]cc1C(NC1CC1)=O Chemical compound Cc1c(/C(/N(C(OCOC(Cc(cc2)ccc2OCC(O)=O)=O)=O)c2c(C)ccc(C(NC3CC3)=O)c2)=N\C=[N-])[nH]cc1C(NC1CC1)=O KZYFIDCFFKLEKC-USLOJTSYSA-N 0.000 description 1
- YKOJNXDHDZBSGT-UHFFFAOYSA-N Cc1c(/C(/Nc2cc(C(NC3CC3)=O)ccc2C)=N\C=N)[nH]cc1C(N(C1CC1)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O)=O Chemical compound Cc1c(/C(/Nc2cc(C(NC3CC3)=O)ccc2C)=N\C=N)[nH]cc1C(N(C1CC1)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O)=O YKOJNXDHDZBSGT-UHFFFAOYSA-N 0.000 description 1
- SAVTXAPRCGFRMQ-UHFFFAOYSA-N Cc1c(/C(/Nc2cc(C(Nc3n[o]cc3)=O)ccc2C)=N\C=N)[nH]cc1C(N(C1CC1)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O)=O Chemical compound Cc1c(/C(/Nc2cc(C(Nc3n[o]cc3)=O)ccc2C)=N\C=N)[nH]cc1C(N(C1CC1)C(OCOC(c(cc1)ccc1OP(O)(O)=O)=O)=O)=O SAVTXAPRCGFRMQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77985106P | 2006-03-07 | 2006-03-07 | |
| PCT/US2007/063250 WO2007103839A2 (en) | 2006-03-07 | 2007-03-05 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535295A JP2009535295A (ja) | 2009-10-01 |
| JP2009535295A5 true JP2009535295A5 (https=) | 2010-02-25 |
Family
ID=38475749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558486A Pending JP2009535295A (ja) | 2006-03-07 | 2007-03-05 | キナーゼ阻害剤として有用なピロロトリアジンアニリンプロドラッグ化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7572795B2 (https=) |
| EP (1) | EP2001886A2 (https=) |
| JP (1) | JP2009535295A (https=) |
| KR (1) | KR20080107408A (https=) |
| CN (1) | CN101395158A (https=) |
| AR (1) | AR059778A1 (https=) |
| AU (1) | AU2007223342A1 (https=) |
| BR (1) | BRPI0708644A2 (https=) |
| CA (1) | CA2645031A1 (https=) |
| EA (1) | EA200801945A1 (https=) |
| IL (1) | IL193653A0 (https=) |
| MX (1) | MX2008011136A (https=) |
| NO (1) | NO20083717L (https=) |
| PE (1) | PE20080139A1 (https=) |
| TW (1) | TW200804390A (https=) |
| WO (1) | WO2007103839A2 (https=) |
| ZA (1) | ZA200807459B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101025675B1 (ko) * | 2002-04-23 | 2011-03-30 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물 |
| CN101395158A (zh) * | 2006-03-07 | 2009-03-25 | 百时美施贵宝公司 | 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物 |
| WO2009158450A1 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof |
| WO2009158446A2 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof |
| HRP20140640T1 (hr) * | 2008-08-19 | 2014-11-21 | Xenoport, Inc. | Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| CA2937222C (en) * | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| CN102596921B (zh) * | 2009-09-29 | 2015-04-29 | 葛兰素集团有限公司 | 新化合物 |
| MX2012003778A (es) * | 2009-09-29 | 2012-06-01 | Glaxo Group Ltd | Compuestos novedosos. |
| CN102918045A (zh) | 2010-03-31 | 2013-02-06 | 百时美施贵宝公司 | 作为蛋白激酶抑制剂的取代的吡咯并三嗪 |
| WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
| CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
| US8901305B2 (en) * | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
| WO2017070135A1 (en) * | 2015-10-20 | 2017-04-27 | Bristol-Myers Squibb Company | Prodrugs of 2-(4-(3-((4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperaz in-1-yl)propanamide derivatives as ck2 inhibitors for the treatment of cancer |
| AU2017246228B2 (en) * | 2016-04-04 | 2021-04-15 | Chemocentryx, Inc. | Soluble C5aR antagonists |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN110590839B (zh) * | 2018-06-13 | 2022-04-05 | 四川海思科制药有限公司 | 一种乐伐替尼衍生物及制备方法和用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629301A (en) | 1969-10-24 | 1971-12-21 | Du Pont | 3 3-difluoro-2-substituted steroids and their preparation |
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| PL187516B1 (pl) | 1996-01-11 | 2004-07-30 | Smithkline Beecham Corp | Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| EP0983260A2 (en) | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
| US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| CA2342251A1 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| WO2001014378A1 (en) | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| DE60018037T2 (de) | 1999-11-10 | 2006-01-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren |
| US6756376B1 (en) | 1999-11-15 | 2004-06-29 | Shionogi & Co., Ltd. | Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities |
| US6376548B1 (en) | 2000-01-28 | 2002-04-23 | Rohm And Haas Company | Enhanced propertied pesticides |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| JP2005529890A (ja) | 2002-04-23 | 2005-10-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物 |
| KR101025675B1 (ko) | 2002-04-23 | 2011-03-30 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물 |
| US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004013145A1 (en) | 2002-08-02 | 2004-02-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| BRPI0407282A (pt) * | 2003-02-05 | 2006-01-31 | Bristol Myers Squibb Co | Processo para preparação de inibidores de pirrolotriazina cinase |
| US7265140B2 (en) | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
| WO2007138381A2 (en) | 2005-10-14 | 2007-12-06 | Targanta Therapeutics Inc. | Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections |
| CN101395158A (zh) * | 2006-03-07 | 2009-03-25 | 百时美施贵宝公司 | 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物 |
-
2007
- 2007-03-05 CN CNA2007800079168A patent/CN101395158A/zh active Pending
- 2007-03-05 CA CA002645031A patent/CA2645031A1/en not_active Abandoned
- 2007-03-05 MX MX2008011136A patent/MX2008011136A/es not_active Application Discontinuation
- 2007-03-05 AU AU2007223342A patent/AU2007223342A1/en not_active Abandoned
- 2007-03-05 WO PCT/US2007/063250 patent/WO2007103839A2/en not_active Ceased
- 2007-03-05 BR BRPI0708644-0A patent/BRPI0708644A2/pt not_active IP Right Cessation
- 2007-03-05 KR KR1020087021851A patent/KR20080107408A/ko not_active Withdrawn
- 2007-03-05 EP EP07757860A patent/EP2001886A2/en not_active Withdrawn
- 2007-03-05 JP JP2008558486A patent/JP2009535295A/ja active Pending
- 2007-03-05 EA EA200801945A patent/EA200801945A1/ru unknown
- 2007-03-06 US US11/682,331 patent/US7572795B2/en active Active
- 2007-03-06 PE PE2007000242A patent/PE20080139A1/es not_active Application Discontinuation
- 2007-03-07 AR ARP070100944A patent/AR059778A1/es unknown
- 2007-03-07 TW TW096107889A patent/TW200804390A/zh unknown
-
2008
- 2008-08-24 IL IL193653A patent/IL193653A0/en unknown
- 2008-08-29 NO NO20083717A patent/NO20083717L/no not_active Application Discontinuation
- 2008-08-29 ZA ZA200807459A patent/ZA200807459B/xx unknown
-
2009
- 2009-02-12 US US12/370,081 patent/US20090156555A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535295A5 (https=) | ||
| JP2013056886A5 (https=) | ||
| AU2013302519B2 (en) | Deuterated baricitinib | |
| RU2110993C1 (ru) | Синергетическая фармацевтическая комбинация, фармацевтическая композиция и способ лечения или профилактики вич-инфекций | |
| US8877801B2 (en) | Compounds and compositions as selective estrogen receptor degraders | |
| JP2010523522A5 (https=) | ||
| JP2005194283A5 (https=) | ||
| MY143757A (en) | 3,7-diamond-10h-phenothiazine salts and their use | |
| JP2011513410A5 (https=) | ||
| JP2010518067A (ja) | 抗寄生虫剤 | |
| CN106117194A (zh) | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 | |
| JP2010510215A5 (https=) | ||
| SI1682536T1 (sl) | Postopek izdelave kalcijeve soli rosuvastatin-(E)-7-(4-(4-fluorofenil) -6-izopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il) (3r,5s)-3,5- dihidroksihept-6-enojske kisline in njenih kristalnih vmesnih spojin | |
| JP2024511973A (ja) | Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤 | |
| JP2010513285A5 (https=) | ||
| JP2001507023A (ja) | トリアゾロ［４，５−ｄ］ピリミジニル誘導体および医薬としてのその使用 | |
| JP2009511508A5 (https=) | ||
| JP2011520903A5 (https=) | ||
| EP3255043A3 (en) | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3- methylazetidine-1-sulfonamide as chemokine receptor modulator | |
| JPH10139668A (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| JP2002517443A (ja) | Ｈｉｖプロテアーゼ阻害剤の浸透を増加させる方法および組成物 | |
| JP2004525183A5 (https=) | ||
| JP2022520361A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| JP2014511897A5 (https=) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral |